Melanotan 2: Clinical Evidence for MT-2-Induced Melanogenesis

Melanotan 2 (MT-2) is a cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the early 1990s. Two Phase I clinical trials established that subcutaneous administration produces measurable melanogenesis — skin darkening — in human subjects.

Phase I Trial: Dorr et al. (1996)

The first published human data came from Dorr et al. at the University of Arizona Cancer Center, published in Life Sciences in 1996 (PMID: 8637402). Three male volunteers received subcutaneous injections of MT-2 at doses of 0.01 to 0.03 mg/kg in a single-blind, placebo-controlled design.

Key Findings

• Dose-dependent increases in tanning were observed in all subjects who received MT-2, confirmed by skin colorimetry
• Melanogenesis began within days of the first injection and was sustained over the observation period
• Side effects were primarily nausea and facial flushing — transient and dose-related
• Spontaneous erections were reported as an unexpected finding, leading to a subsequent trial

Phase I Crossover Trial: Wessells et al. (1998)

Wessells et al. conducted a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction, published in the Journal of Urology (1998). Participants received MT-2 at 0.025 mg/kg or placebo subcutaneously and were monitored with RigiScan devices for rigidity events.

Key Findings

• MT-2 produced significantly more erectile events than placebo in 8 of 10 subjects
• Rigidity responses were dose-dependent and appeared within 1–2 hours of injection
• Nausea was reported in 30% of injections — the primary limiting adverse event

Mechanism: α-MSH and MC1R

MT-2 is a potent agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. MC1R is expressed on melanocytes; activation stimulates melanin synthesis and transfer to keratinocytes, producing skin darkening without UV exposure. MC4R activation in the hypothalamus is responsible for the observed effects on appetite and sexual function.

Evidence Context

Both trials were small (3 and 10 subjects respectively) and used single doses or short protocols. They established proof-of-concept for melanogenesis in humans — a biologically significant finding — but long-term safety data in humans is limited. The tanning response observed is consistent with the mechanism and has been reproduced in subsequent self-reported research use, though large controlled trials have not followed.